NRAS mutations are also common in melanoma occurring in up to 30% of cases, and as the occurrence of NRAS or BRAF mutation in melanoma is mutually exclusive, up to 90% of melanomas harbour a mutated, hyperactive Ras–RAF signalling pathway (Davies et al, 2002). This evidence concerns the gene BRAF and melanoma.